Article info

Extended report
Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy

Authors

  1. Correspondence to Professor Josef S Smolen, Division of Rheumatology, Department of Medicine III, Medical University of Vienna and 2nd Department of Medicine, Hietzing Hospital, Waehringer Guertel 18–20, Vienna A-1090, Austria; josef.smolen{at}wienkav.at
View Full Text

Citation

Smolen JS, Weinblatt ME, Sheng S, et al
Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy

Publication history

  • Received December 23, 2013
  • Revised March 3, 2014
  • Accepted March 6, 2014
  • First published April 3, 2014.
Online issue publication 
July 31, 2014

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.